With psilocybin among the favorites within psychedelics, Core One Labs Inc. (OTCQB: CLABF) is joining Optimi Health (OTC PINK: OPTHF) to formally begin sales for its own biosynthetic API psilocybin product.

On August 26, the company began discussions with a development and manufacturing partner regarding the commercial scale and GMP-compliant production of Core One’s Active Pharmaceutical Ingredient (API) psilocybin product.

To that end, Core One’s representatives contacted several pharmaceutical and publicly traded psychedelic …

Full story available on Benzinga.com